Paratek Pharmaceuticals (PRTK) Lowered to Hold at Zacks Investment Research

Paratek Pharmaceuticals (NASDAQ:PRTK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday.

According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “

PRTK has been the topic of several other research reports. Cantor Fitzgerald restated a “buy” rating and set a $50.00 price objective on shares of Paratek Pharmaceuticals in a report on Thursday, September 21st. Robert W. Baird restated a “buy” rating and set a $40.00 price objective on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. Guggenheim began coverage on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. They set a “buy” rating and a $44.00 price objective on the stock. BidaskClub downgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 2nd. Finally, ValuEngine downgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $40.00.

Paratek Pharmaceuticals (NASDAQ:PRTK) traded down $0.08 during trading on Thursday, hitting $17.67. 332,400 shares of the company were exchanged, compared to its average volume of 313,000. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49. Paratek Pharmaceuticals has a 52 week low of $13.95 and a 52 week high of $29.00. The firm has a market cap of $495.95, a P/E ratio of -4.74 and a beta of 0.69.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.93) by $0.16. Paratek Pharmaceuticals had a negative net margin of 1,236.38% and a negative return on equity of 100.84%. analysts anticipate that Paratek Pharmaceuticals will post -3.32 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Legal & General Group Plc raised its holdings in shares of Paratek Pharmaceuticals by 13.3% in the second quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after purchasing an additional 687 shares during the last quarter. Wells Fargo & Company MN grew its position in Paratek Pharmaceuticals by 9.7% during the second quarter. Wells Fargo & Company MN now owns 17,075 shares of the specialty pharmaceutical company’s stock valued at $411,000 after buying an additional 1,509 shares during the period. ProShare Advisors LLC grew its position in Paratek Pharmaceuticals by 14.1% during the second quarter. ProShare Advisors LLC now owns 16,191 shares of the specialty pharmaceutical company’s stock valued at $390,000 after buying an additional 2,005 shares during the period. Nationwide Fund Advisors grew its position in Paratek Pharmaceuticals by 22.9% during the second quarter. Nationwide Fund Advisors now owns 13,355 shares of the specialty pharmaceutical company’s stock valued at $322,000 after buying an additional 2,492 shares during the period. Finally, Alps Advisors Inc. grew its position in Paratek Pharmaceuticals by 10.2% during the third quarter. Alps Advisors Inc. now owns 27,339 shares of the specialty pharmaceutical company’s stock valued at $686,000 after buying an additional 2,530 shares during the period. Institutional investors own 84.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Paratek Pharmaceuticals (PRTK) Lowered to Hold at Zacks Investment Research” was first published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.truebluetribune.com/2018/01/18/paratek-pharmaceuticals-prtk-lowered-to-hold-at-zacks-investment-research.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply